Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Entyvio is a prescription integrin receptor antagonist containing vedolizumab. It is approved in adults for moderately to severely active ulcerative colitis and Crohn disease. Treatment starts with intravenous infusions, and patients can continue intravenous therapy or switch to a subcutaneous prefilled syringe or pen after the initial doses.
read more about entyvio ...Vedolizumab binds the alpha4beta7 integrin on selected memory T lymphocytes and blocks its interaction with MAdCAM-1 on gut endothelial cells. This inhibits migration of these lymphocytes into inflamed gastrointestinal tissue and reduces a pathway involved in chronic intestinal inflammation.
Entyvio treats adults with moderately to severely active ulcerative colitis or Crohn disease. Before treatment, tuberculosis assessment is considered and immunizations are updated. Current U.S. labeling does not establish pediatric safety and efficacy.
Treatment starts with 300 mg by intravenous infusion at week 0 and week 2. At week 6, patients can receive another 300 mg intravenous infusion followed by 300 mg every eight weeks, or switch to 108 mg subcutaneously every two weeks. Treatment is discontinued when there is no therapeutic benefit by week 14.
Serious concerns include infusion-related or hypersensitivity reactions, infections, liver injury, and a potential risk of progressive multifocal leukoencephalopathy. Treatment does not start during a clinically significant active infection. A serious infection that develops during therapy calls for withholding Entyvio until the infection resolves.
Entyvio treats moderately to severely active ulcerative colitis and Crohn disease in adults.
The first two doses are 300 mg intravenous infusions at week 0 and week 2.
Yes. After the initial intravenous doses, patients can switch to 108 mg subcutaneously every two weeks.
Current labeling calls for discontinuation when there is no evidence of therapeutic benefit by week 14.
ENTYVIO (Vedolizumab) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6e94621c-1a95-4af9-98d1-52b9e6f1949c. Date Accessed September 29, 2026.
ENTYVIO Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125476s66lbl.pdf. Date Accessed September 29, 2026.
Purple Book Product Details for Entyvio. https://purplebooksearch.fda.gov/index.cfm?blaNo=125476&event=productdetails. Date Accessed September 29, 2026.
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis. https://pubmed.ncbi.nlm.nih.gov/23964932/. Date Accessed September 29, 2026.
Vedolizumab Injection: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a614034.html. Date Accessed September 29, 2026.